Immunotech Biopharm Ltd (6978.HK)

HKD 2.47

(8.33%)

Total Liabilities Summary of Immunotech Biopharm Ltd

Immunotech Biopharm Ltd's latest annual total liabilities in 2023 was 675.39 Million CNY , up 81.04% from previous year.
Immunotech Biopharm Ltd's latest quarterly total liabilities in 2024 Q1 was 641.38 Million CNY , down -5.04% from previous quarter.
Immunotech Biopharm Ltd reported annual total liabilities of 373.06 Million CNY in 2022, up 35.9% from previous year.
Immunotech Biopharm Ltd reported annual total liabilities of 274.51 Million CNY in 2021, up 237.31% from previous year.
Immunotech Biopharm Ltd reported quarterly total liabilities of 641.38 Million CNY for 2024 Q1, down -5.04% from previous quarter.
Immunotech Biopharm Ltd reported quarterly total liabilities of 650.02 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Immunotech Biopharm Ltd (2023 - 2018)

Historical Annual Total Liabilities of Immunotech Biopharm Ltd (2023 - 2018)

Year	Total Liabilities	Total Liabilities Growth
2023	675.39 Million CNY	81.04%
2022	373.06 Million CNY	35.9%
2021	274.51 Million CNY	237.31%
2020	81.38 Million CNY	-67.0%
2019	246.63 Million CNY	292.01%
2018	62.91 Million CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	641.38 Million CNY	0.0%
2024 Q1	641.38 Million CNY	-5.04%
2023 Q2	650.02 Million CNY	0.0%
2023 FY	675.39 Million CNY	81.04%
2023 Q1	650.02 Million CNY	74.24%
2023 Q4	675.39 Million CNY	0.0%
2023 Q3	675.39 Million CNY	3.9%
2022 Q4	373.06 Million CNY	0.0%
2022 Q3	373.06 Million CNY	26.9%
2022 Q2	293.98 Million CNY	0.0%
2022 Q1	293.98 Million CNY	7.09%
2022 FY	373.06 Million CNY	35.9%
2021 Q1	91.43 Million CNY	12.35%
2021 Q2	91.43 Million CNY	0.0%
2021 FY	274.51 Million CNY	237.31%
2021 Q4	274.51 Million CNY	0.0%
2021 Q3	274.51 Million CNY	200.23%
2020 Q4	81.38 Million CNY	0.0%
2020 FY	81.38 Million CNY	-67.0%
2020 Q3	81.38 Million CNY	-72.23%
2020 Q2	293.08 Million CNY	188.57%
2020 Q1	101.56 Million CNY	-58.82%
2019 Q3	74.52 Million CNY	0.0%
2019 Q1	- CNY	0.0%
2019 Q4	246.63 Million CNY	230.93%
2019 FY	246.63 Million CNY	292.01%
2018 FY	62.91 Million CNY	0.0%

Peer Total Liabilities Comparison of Immunotech Biopharm Ltd

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	-341.96%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	90.431%